René Bernards

Closest collaborators

The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Sara Mainardi · 3 shared papers, 2022–2026 · strength 0.72
   • Paper A large-scale organoid-based screening platform to advance drug repurposing in pancreatic cancer. DOI 10.1016/j.xgen.2022.100100↗
   • Paper CRISPR knockout screens reveal JUN as the master mediator of resistance to MAPK inhibition in KRAS-mutant pancreatic ca… DOI 10.1186/s13046-025-03616-z↗
   • Paper Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pan… DOI 10.1016/j.xcrm.2022.100815↗
2. Antonio Mulero‐Sánchez · 2 shared papers, 2022–2026 · strength 0.39
   • Paper CRISPR knockout screens reveal JUN as the master mediator of resistance to MAPK inhibition in KRAS-mutant pancreatic ca… DOI 10.1186/s13046-025-03616-z↗
   • Paper Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pan… DOI 10.1016/j.xcrm.2022.100815↗
3. Emilie M.J. van Brummelen · 3 shared papers, 2020–2021 · strength 0.30
   • Paper Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic… DOI 10.1002/onco.13631↗
   • Paper Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic… DOI 10.1007/s00280-020-04066-4↗
   • Paper Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-… DOI 10.1038/s41416-020-0776-z↗
4. Sanne C.F.A. Huijberts · 3 shared papers, 2020–2021 · strength 0.30
   • Paper Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic… DOI 10.1002/onco.13631↗
   • Paper Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic… DOI 10.1007/s00280-020-04066-4↗
   • Paper Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-… DOI 10.1038/s41416-020-0776-z↗
5. Frans L. Opdam · 3 shared papers, 2020–2021 · strength 0.30
   • Paper Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic… DOI 10.1002/onco.13631↗
   • Paper Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic… DOI 10.1007/s00280-020-04066-4↗
   • Paper Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-… DOI 10.1038/s41416-020-0776-z↗
6. Robin M.J.M. van Geel · 3 shared papers, 2020–2021 · strength 0.30
   • Paper Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic… DOI 10.1002/onco.13631↗
   • Paper Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic… DOI 10.1007/s00280-020-04066-4↗
   • Paper Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-… DOI 10.1038/s41416-020-0776-z↗
7. Jan H.M. Schellens · 3 shared papers, 2020–2021 · strength 0.30
   • Paper Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic… DOI 10.1002/onco.13631↗
   • Paper Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic… DOI 10.1007/s00280-020-04066-4↗
   • Paper Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-… DOI 10.1038/s41416-020-0776-z↗
8. Wolfgang Weber · 1 shared paper, 2022 · strength 0.11
   • Paper Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pan… DOI 10.1016/j.xcrm.2022.100815↗
9. Katrin J. Frank · 1 shared paper, 2022 · strength 0.11
   • Paper Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pan… DOI 10.1016/j.xcrm.2022.100815↗
10. Marina Lesina · 1 shared paper, 2022 · strength 0.11
    • Paper Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pan… DOI 10.1016/j.xcrm.2022.100815↗
11. Kıvanç Görgülü · 1 shared paper, 2022 · strength 0.11
    • Paper Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pan… DOI 10.1016/j.xcrm.2022.100815↗
12. Derya Kabacaoğlu · 1 shared paper, 2022 · strength 0.11
    • Paper Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pan… DOI 10.1016/j.xcrm.2022.100815↗
13. Dietrich Alexander Ruess · 1 shared paper, 2022 · strength 0.11
    • Paper Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pan… DOI 10.1016/j.xcrm.2022.100815↗
14. Bruno Sáinz · 1 shared paper, 2022 · strength 0.11
    • Paper Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pan… DOI 10.1016/j.xcrm.2022.100815↗
15. Hana Algül · 1 shared paper, 2022 · strength 0.11
    • Paper Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pan… DOI 10.1016/j.xcrm.2022.100815↗
16. Ferry A.L.M. Eskens · 1 shared paper, 2020 · strength 0.09
    • Paper Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-… DOI 10.1038/s41416-020-0776-z↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.